发明名称 |
Factor IX analogues having prolonged in vivo half life |
摘要 |
The invention is related to FIX analogues which have an increased circulation time in the blood stream before activation compared to that that of native FIX (and a week after injection to a patient retains at least about 5% of the FIX activity compared to the initial activity peak value reached after injection). The claimed FIX analogues comprise an inserted cysteine residue which has been further modified by conjugation with a chemical group increasing the molecular weight of the FIX analogue. |
申请公布号 |
AU2007253264(A1) |
申请公布日期 |
2007.11.29 |
申请号 |
AU20070253264 |
申请日期 |
2007.05.24 |
申请人 |
NOVO NORDISK HEALTH CARE AG |
发明人 |
HENNING RALF STENNICKE;HENRIK OSTERGAARD;THOMAS DOCK STEENSTRUP;OLE HVILSTED OLSEN |
分类号 |
C12N9/64;A61K38/48;A61P7/04 |
主分类号 |
C12N9/64 |
代理机构 |
|
代理人 |
|
主权项 |
|
地址 |
|